Mr Mark David Francom, FNP | |
2920 N 4th St, Flagstaff, AZ 86004-1816 | |
(928) 213-6100 | |
Not Available |
Full Name | Mr Mark David Francom |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2920 N 4th St, Flagstaff, Arizona |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821378118 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 2090088982 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Mark David Francom, FNP Po Box 3630, Flagstaff, AZ 86003-3630 Ph: (928) 213-6100 | Mr Mark David Francom, FNP 2920 N 4th St, Flagstaff, AZ 86004-1816 Ph: (928) 213-6100 |
News Archive
Chromosomes - long, linear DNA molecules - are capped at their ends with special DNA structures called telomeres and an assortment of proteins, which together act as a protective sheath. Telomeres are maintained through the interactions between an enzyme, telomerase, and several accessory proteins. Researchers at The Wistar Institute have defined the structure of one of these critical proteins in yeast.
"Drug makers, advocacy groups, biotechnology firms and insurance companies have ratcheted up efforts to offer their two cents - and in most cases much, much more - in influencing the health care legislation now working its way through Congress," The New York Times reports.
Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.
IBM and Cellomics have announced they have launched a customized information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better understand how potential drug candidates or targets of interest affect cellular function.
ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent, tecarfarin (ATI-5923).
› Verified 1 days ago
Kaitlyn Losey, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-773-2451 Fax: 928-214-2925 | |
Charles Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2920 N 4th St, Flagstaff, AZ 86004 Phone: 928-213-6100 Fax: 928-774-4808 | |
Christine Ameduri, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1110 E Route 66 Ste 100, Flagstaff, AZ 86001 Phone: 928-773-9695 Fax: 928-773-0208 | |
Donna Nelson, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: South San Francisco And Dome Access, Bldg 41 Nau Campus, Flagstaff, AZ 86011 Phone: 928-523-6343 | |
Dr. Eric Henley, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2920 N 4th St, Flagstaff, AZ 86004 Phone: 928-213-6100 Fax: 928-774-4808 | |
Dr. Charles Dennis Bendixen, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1955 N Meteor Dr, Flagstaff, AZ 86001 Phone: 928-774-2061 | |
Dr. Jane Ellen Dill, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 2920 N 4th St, Flagstaff, AZ 86004 Phone: 928-213-6100 Fax: 928-774-4808 |